BCCOY.US BICO Group AB (publ)
- Market cap
- USD 174M
- P/E
- -
- P/B
- 1.29x
- ROE
- -38.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BCCOY.US undervalued?
Graham numberThe Graham number of BICO Group AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BICO Group AB (publ) fundamental analysis
No fundamental analysis for BICO Group AB (publ) yet.
BICO Group AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BICO Group AB (publ)
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solu…
Full company profileBICO Group AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BICO Group AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 13.2M | 45.3M | 105M | 177M | 1.26B | 2.24B | 2.01B | 1.95B | 1.41B | 1.52B |
| Gross Profit | - | 12.6M | 39.6M | 91.4M | 164M | 1.00B | 1.83B | 993M | 1.01B | 547M | 859M |
| Operating Income | - | -23.0K | 372K | -3.75M | -66.1M | -160M | -618M | -293M | -289M | -237M | -83.8M |
| EBITDA | - | 696K | 3.72M | 5.82M | -39.5M | 31.8M | 322M | 443M | 194M | -32.8M | 150M |
| Net Income | - | 155K | 1.18M | 581K | -61.9M | -229M | -836M | -1.17B | -5.50M | -1.02B | -520M |
| EPS | - | 0.00 | 0.01 | 0.00 | -0.37 | -0.93 | -3.12 | -17 | -0.02 | -3.63 | -1.84 |
| Balance Sheet | |||||||||||
| Total Assets | 8.03M | 69.2M | 195M | 603M | 1.65B | 9.75B | 10.2B | 7.90B | 5.48B | 3.70B | 2.58B |
| Total Liabilities | 5.72M | 9.17M | 8.82M | 53.5M | 127M | 2.95B | 3.26B | 2.99B | 2.48B | 1.95B | 1.23B |
| Shareholders' Equity | 2.32M | 60.0M | 186M | 550M | 1.52B | 6.77B | 6.91B | 4.91B | 2.99B | 1.75B | 1.35B |
| Cash & Short-term Investments | 3.06M | 44.6M | 137M | 109M | 996M | 1.48B | 925M | 804M | 85.6M | 1.28B | 555M |
| Total Debt | 3.00M | 3.00M | 600K | 600K | 62.5M | 1.61B | 1.85B | - | 1.76B | 1.51B | 697M |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | -179K | -12.3M | -15.8M | -71.8M | -409M | -269M | -72.1M | 158M | 64.3M | -70.9M |
| Capital Expenditure | - | 13.1M | 19.2M | 35.7M | 82.3M | 267M | 530M | 454M | 44.1M | 12.5M | 25.1M |
| Free Cash Flow | - | -13.3M | -31.5M | -51.6M | -154M | -676M | -799M | -526M | 114M | 51.8M | -96.0M |
| Ratios | |||||||||||
| ROE | - | 0.3% | 0.6% | 0.1% | -4.1% | -3.4% | -12.1% | -23.9% | -0.2% | -58.5% | -38.6% |
| ROA | - | 0.2% | 0.6% | 0.1% | -3.8% | -2.3% | -8.2% | -14.8% | -0.1% | -27.7% | -20.2% |
| Net Profit Margin | - | 1.2% | 2.6% | 0.6% | -35.0% | -18.2% | -37.3% | -58.3% | -0.3% | -72.7% | -34.2% |
| Debt to Equity | 1.30x | 0.05x | 0.00x | 0.00x | 0.04x | 0.24x | 0.27x | - | 0.59x | 0.86x | 0.52x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BICO Group AB (publ) dividends
BICO Group AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns BICO Group AB (publ)
Ownership data of BICO Group AB (publ) is not available yet.
BICO Group AB (publ) company profile
- Company name
- BICO Group AB (publ)
- Ticker
- BCCOY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 554
- Fiscal year end
- December
- Address
- Grafiska vägen 2B, Gothenburg, Sweden, 412 63
- Phone
- 46 7 35 46 57 77
- Website
- bico.com
About BICO Group AB (publ)
BICO Group AB (publ) provides hardware, laboratory automation, and software solutions in North America, Europe, Asia, and internationally. It operates through two segments: Life Science Solutions and Lab Automation. The Bioprinting segment offers 3D bioprinters and bioinks with a range of technologies for various applications, resolutions, and volume/speed requirements, as well as provides services focused on accelerating drug discovery and development. The Life Science Solutions segment supplies lab instrumentation, consumables and applications in cell culture, cell imaging, cell sorting, and sample preparation for different analytics, such as genomics, as well as offers instruments and solutions for the manufacturing of diagnostics, as well as consumables. The Lab Automation segment provides the proprietary and hardware-agnostic Green Button Go Suite software for connected workflows, as well as automation technology integration, and consulting and engineering services to design, build, and install automated laboratory systems. In addition, the company offers a range of services and consumables such as reagents, bioinks, plates, and tissue models. It serves pharma and biopharma, biotech, diagnostics, academia and research, and cosmetic industries. The company offers its products through sales organizations, as well as through distributor network. BICO Group AB (publ) was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. The company was incorporated in 2016 and is headquartered in Gothenburg, Sweden.
BICO Group AB (publ) management
10- Ms. Maria ForssSenior Advisor · born 1972
- Mr. Anders FogelbergPresident & CEO · born 1975
- Ms. Ewa LinsaterChief Financial Officer · born 1970
- Mr. Jesper HagbergChief Operations & Digital Officer · born 1969
- Ms. Asa HillstenSenior VP & Head of Investor Relations · born 1975
- Mr. Lars RisbergGeneral Counsel · born 1968
- Ms. Catharina NordlundGlobal Head of Human Resources · born 1968
- Ms. Itedale Namro RedwanChief Scientific Officer - Bioprinting
- Ms. Erica BellSenior VP & Chief People Officer · born 1973
- Andreas JoersjoAdvisor